L'intérêt à découvert pour Coincheck Group donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Coincheck Group. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Coincheck Group (NASDAQ:CNCK) Stock, Rapport sur les intérêts à découvert

Coincheck Group

Coincheck Group NV is a digital asset trading service company. It operates multi-cryptocurrency marketplaces and crypto asset exchanges in Japan and marketplace and exchange platforms on which diverse cryptocurrencies, including Bitcoin and Ethereum, are held and exchanged, and offers other retail-focused crypto services. It is also increasing user's access to digital products and solutions beyond cryptocurrencies, such as non-fungible tokens (NFTs). The company manages its business in one operating and reportable segment: Crypto Asset.

Coincheck Group NV

WIIM

BITF

BTBT

BTCM

BTCS

BTDR

CIFR

CLSK

CNCK

MARA

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

MSTR

RIOT

WULF

Shares of crypto-related companies are trading lower after Fed Chair Powell left rates unchanged. Fed Chair Powell mentioned that inflation is above target.

As advancements in cancer treatment continue to evolve, the pursuit of more effective therapies for metastatic colorectal cancer remains a critical focus in the pharmaceutical industry. Cardiff Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) on Tuesday released data from the ongoing CRDF-004 Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">metastatic colorectal cancer (mCRC)</a>.
Patients were randomized to one of six arms, including 20mg of onvansertib plus SoC, 30mg of onvansertib plus SoC, or SoC alone.
The overall objective response rate (ORR) was 59% on the high dose and 50% in the 20 mg dose, compared to a 43% response <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46704927/cardiff-oncology-announces-positive-data-from-ongoing-randomized-phase-2-first-line-ras-mutated-mc" rel="noreferrer noopener">rate in the control arm</a>.
After removing the ORRs at 6 months, the confirmed ORRs for the high-dose, low-dose, and control arms were 49%, 42%, and 30%, respectively.
<h2 class="wp-block-heading">Onvansertib Shows Promise With High Response Rates</h2>
For comparison, December 2024 data showed an ORR of 57% in all onvansertib patients, with 50% in the 20mg dose of onvansertib + SoC arm and 64% in the 30mg dose of onvansertib + SoC arm, compared to <a target="_blank" href="https://www.benzinga.com/24/12/42416310/whats-going-on-with-cardiff-oncology-stock-on-tuesday" rel="noreferrer noopener">33% in the SoC alone arm</a>.
Spider Plots, displaying the change in tumor size from baseline for each patient over time, demonstrate deeper responses in patients receiving the 30mg dose of onvansertib combined with the SoC compared to the control arm and the 20mg dose of onvansertib arm.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46053581/exelixis-targets-5-billion-in-sales-with-promising-data-in-key-colorectal-cancer-drug-trial-stock-soars" rel="noreferrer noopener">Exelixis&#8217; Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars</a>
Both the 20mg and 30mg onvansertib arms demonstrated an early separation of the progression-free Survival (PFS) curves compared to the control arm at a median follow-up time of 6 months.
While the median PFS has not been reached, a dose-dependent effect was observed in favor of the 30mg onvansertib dose.
The safety analysis was conducted for the 104 patients dosed in the trial. Onvansertib, in combination with chemotherapy and bevacizumab, was well-tolerated, and no major or unexpected toxicities were observed.
<h2 class="wp-block-heading">Can This Drug Change Colorectal Cancer Outcomes?</h2>
Grade 3 or higher adverse events were infrequent, with neutropenia being the most common treatment-emergent adverse event associated with onvansertib.
Update on first-line mCRC program expected by the first quarter of 2026.
William Blair believes the current data on onvansertib justifies further investment, including moving forward with a Phase 3 trial.
The overall data shows that onvansertib is clearly effective, which analyst Andy Hsieh says weakens the bearish argument against the stock.
The key question is whether the ORR improvement will result in a meaningful gain in PFS, the main measure needed for approval.
<h2 class="wp-block-heading">How Dose Variations Impact Patient Survival Rates</h2>
Looking at past data, even a modest improvement in response rates—like the 11% increase seen in the Phase 3 TRIBE study—can result in a successful outcome in key trials, especially if it also boosts PFS.
In the Phase 3 BREAKWATER study for BRAF-mutated colorectal cancer, a 20% jump in response rate led to meaningful gains in PFS and overall survival.
Analyst Hsieh writes that the current valuation reflects considerable skepticism regarding the compound's clinical profile, which William Blair disagrees with.
William Blair holds a bullish view that onvansertib could potentially disrupt the RAS-mutated frontline mCRC treatment paradigm. <a target="_blank" href="https://www.benzinga.com/quote/CRDF/analyst-ratings" rel="noreferrer noopener">Reiterates Outperform rating</a>.
CRDF Price Action: Cardiff Oncology shares were down 19.94% at $2.65 at the time of publication on Wednesday<a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">, according to Benzinga Pro data.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46731635/american-electric-power-lifts-annual-gaap-outlook-to-announce-70-billion-capital-plan" target="_blank" rel="noreferrer noopener">American Electric Power Lifts Annual GAAP Outlook, To Announce $70 Billion Capital Plan</a></li>
</ul>
Photo: jittawit21/Shutterstock

Analyst Color

Biotech

News

Health Care

Analyst Ratings

Movers

Trading Ideas

General

CRDF

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

Global

Reuters Cites Statement Saying Brazil's Trade Panel Decides To Bring Forward Tariff Increase Schedule For Electric, Hybrid Vehicles; 35% Tariff On Electric, Hybrid Vehicles To Start On Jan, 2027 Vs July, 2028 Previously

<a href="https://www.bloomberg.com/news/articles/2025-07-30/us-hits-iran-oil-trading-network-in-sanctions-crackdown?srnd=homepage-americas" title="https://www.bloomberg.com/news/articles/2025-07-30/us-hits-iran-oil-trading-network-in-sanctions-crackdown?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-07-30/us-hits-iran-oil-trading-network-in-sanctions-crackdown?srnd=homepage-americas</a>

Macro Economic Events

Econ #s

Economics

'US Hits Iran Oil-Trading Network in Sweeping Sanctions Crackdown' - Bloomberg News

Polaris Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) reported better-than-expected second-quarter <a href="https://www.benzinga.com/quote/PII/earnings">financial results on Tuesday</a>.
Polaris posted adjusted earnings of 40 cents per share, compared to market estimates of a loss of 4 cents per share. The company's quarterly sales came in at $1.852 billion beating expectations of $1.720 billion.
Polaris said it sees third-quarter sales of $1.600 billion to $1.800 billion, versus estimates of $1.671 billion.
Polaris shares gained 7.8% to trade at $53.32 on Wednesday.
These analysts made changes to their price targets on Polaris following earnings announcement.
<ul class="wp-block-list">
<li>Baird analyst Craig Kennison maintained Polaris with a Neutral and raised the price target from $46 to $55.</li>
<li>RBC Capital analyst Sabahat Khan maintained the stock with a Sector Perform and raised the price target from $34 to $56.</li>
<li>MO Capital analyst Tristan Thomas-Martin maintained Polaris with a Market Perform and raised the price target from $33 to $52.</li>
</ul>
Considering buying PII stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/PII/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="565" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30152021/image-490-1024x565.png" alt="" class="wp-image-1007799" style="width:602px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30152021/image-490-1024x565.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30152021/image-490-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30152021/image-490-768x424.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30152021/image-490.png 1146w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46684052/jim-cramer-prefers-this-financial-stock-over-brighthouse-financial">Jim Cramer Prefers This Financial Stock Over Brighthouse Financial</a></li>
</ul>

Earnings

Price Target

Markets

Polaris Analysts Boost Their Forecasts After Better-Than-Expected Q2 Earnings

Marvell Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) <a target="_blank" href="https://www.benzinga.com/topic/artificial-intelligence" rel="noreferrer noopener">traded</a> higher Wednesday as the AI boom drives major tech companies to accelerate chip upgrades to meet surging global demand and strengthen their competitive positions.
The semiconductor firm, which provides chip design and services across data centers, enterprise networks, consumer tech, telecom infrastructure, and automotive, is benefiting from the renewed momentum.
Rebellions, a South Korea-based AI semiconductor company, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46686169/rebellions-announces-collaboration-with-marvell-to-deliver-custom-ai-infrastructure-for-sovereign-" rel="noreferrer noopener">has partnered with</a> Marvell to develop high-performance, energy-efficient AI systems designed explicitly for sovereign-backed and regionally focused AI initiatives across Asia-Pacific and the Middle East.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46492462/marvell-reshuffles-leadership-as-it-looks-to-reignite-momentum-rebuild-investor-confidence" rel="noreferrer noopener">Marvell Reshuffles Leadership As It Looks To Reignite Momentum, Rebuild Investor Confidence (CORRECTED)</a>
Through this collaboration, Rebellions will design custom AI accelerators using Marvell's advanced silicon platform, which includes cutting-edge packaging, high-speed SerDes, and die-to-die interconnect technology.
The partnership aims to deliver tightly integrated, rack-scale AI inference systems that meet the growing demand for scalable, efficient, and sovereign-controlled AI infrastructure—marking a strategic shift from traditional GPU-based architectures to specialized ASIC-driven solutions tailored for national competitiveness.
Marvell stock has plunged over 25% year-to-date, lagging behind the NASDAQ Composite Index's 10% gains, as concerns about the Trump administration's tariff policy and macroeconomic uncertainties weigh on the stock.
<h2 class="wp-block-heading">Recent AI Policy Shifts</h2>
<a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46700433/broadcom-stock-is-trending-whats-going-on" rel="noreferrer noopener">Recent developments have</a> reshaped the semiconductor industry's interconnected landscape, influencing valuations.
The U.S. recently paused tech export restrictions to China to avoid disrupting trade talks and to support President Donald Trump's efforts to meet with Chinese President Xi Jinping, according to the Financial Times.
This policy shift aligns with Nvidia's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) move to resume H20 AI chip sales to China, effectively reversing an earlier Trump-era ban. The change could benefit U.S. chipmakers as trade negotiations resume in Stockholm.
The White House fueled industry optimism by launching "Winning the AI Race: America's AI Action Plan," detailing over 90 federal initiatives to strengthen AI leadership, innovation, and infrastructure.
The administration plans to fast-track data centers and chip plant permits, boost workforce training, streamline regulations, and ensure fairness in AI-related contracts.
Meanwhile, Nvidia reportedly ordered 300,000 H20 AI chips from contract chipmaker Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), signaling a shift in its production strategy.
Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) also gained ground by capitalizing on AI demand, raising the price of its MI350 chip to $25,000.
Price Action: MRVL stock was trading higher by 7.34% at $82.00 as of last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46717146/united-microelectronics-chief-cautions-currency-trade-policy-could-dampen-gains" target="_blank" rel="noreferrer noopener">United Microelectronics Chief Cautions Currency, Trade Policy Could Dampen Gains</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

Tech

MRVL

NVDA

Marvell Stock Rebounds On AI Momentum, New Global Chip Partnership

Cryptocurrency markets are trading down after the Federal Reserve decided to keep the Federal Funds rate unchanged.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
</tr>
<tr>
<td>Bitcoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$116,074</td>
</tr>
<tr>
<td>Ethereum</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$3,690</td>
</tr>
<tr>
<td>Solana</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$172.30</td>
</tr>
<tr>
<td>XRP</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$3.02</td>
</tr>
<tr>
<td>Dogecoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2109</td>
</tr>
<tr>
<td>Shiba Inu</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001241</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin and Ethereum large transaction decreased by 9.6% and 20.8%, respectively. Daily active addresses moved higher by 2.5% and 12.7%, respectively.</li>
<li>Coinglass data shows 108,863 traders were liquidated in the past 24 hours for $216.32 million.</li>
<li>The top losers in the past 24 hours include SPX6900, Bonk and Conflux.</li>
</ul>
Notable Developments:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46721901/jpmorgan-partners-with-coinbase-to-expand-crypto-access-for-80m-customers">JPMorgan Partners With Coinbase To Expand Crypto Access For 80M Customers</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46720657/turkeys-uber-joins-strategy-tesla-as-bitcoin-treasury-company">&#8216;Turkey&#8217;s Uber&#8217; Joins Strategy, Tesla As Bitcoin Treasury Company</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46729976/300-growth-in-high-inflation-nations-why-stablecoins-are-booming-where-fiat-is-failing">300% Growth In High-Inflation Nations: Why Stablecoins Are Booming Where Fiat Is Failing</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46714238/ethereum-foundation-faces-backlash-for-dumping-100-million-eth-after-saying-believe-in-something">Ethereum Foundation Faces Backlash For &#8216;Dumping&#8217; $100 Million ETH After Saying &#8216;Believe In somETHing&#8217;</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46714603/fis-circle-team-up-to-enable-stablecoin-transactions-for-financial-institutions">FIS, Circle Team Up To Enable Stablecoin Transactions For Financial Institutions</a></li>
</ul>
Trader Notes: Crypto trader CrediBULL Crypto suggests Bitcoin may be mirroring a prior consolidation pattern, referencing his signature "GREEN squiggles." He expects few days of tight, sideways chop before a potential breakout or expansion move.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Think we may be seeing something similar to the GREEN squiggles that we saw in the quoted tweet below. Maybe a few days of tight chop before expansion&#8230;<a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> <a href="https://t.co/IwT9yhxi3m">https://t.co/IwT9yhxi3m</a> <a href="https://t.co/bb4kihn6zM">pic.twitter.com/bb4kihn6zM</a>
&mdash; CrediBULL Crypto (@CredibleCrypto) <a href="https://twitter.com/CredibleCrypto/status/1950610174688788590?ref_src=twsrc%5Etfw">July 30, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Ted Pillows <a href="https://x.com/TedPillows/status/1950593480079941684">highlights</a> that Bitcoin has remained range-bound for weeks, even as global liquidity steadily rises. 
He says the lag is temporary, reminiscent of Q2 behavior, and predicts BTC will soon catch up with macro tailwinds, targeting above $135,000 in Q3.
Henry aka LordOfAlts <a href="https://x.com/LordOfAlts/status/1950429488661352960">remains</a> undeterred by short-term volatility, calling the current pullbacks &#8220;noise within a larger bullish structure.&#8221; 
He notes whales are taking profits and Bitcoin is forming a bullish pennant, with recent downside pressure likely meant to trigger liquidations.
He sees a fourth touch near $114,000 as a key long entry, aligning with his long-term "buy the fear, sell the greed" thesis. Henry expects one final &#8220;Oops moment&#8221; before Bitcoin's next parabolic breakout.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46720222/ethereums-rally-driven-by-fresh-inflows-not-a-rotation-out-of-bitcoin-report">Ethereum&#8217;s Rally Driven By Fresh Inflows, Not A Rotation Out Of Bitcoin: Report</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Decline After Federal Reserve Holds Rates

Waste Management Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) reported better-than-expected earnings for the second quarter, after the <a href="https://www.benzinga.com/quote/WM/earnings">closing bell on Monday.</a>
The company posted quarterly earnings of $1.92 per share which beat the analyst consensus estimate of $1.89 per share. The company reported quarterly sales of $6.430 billion which beat the analyst consensus estimate of $6.369 billion.
&#8220;As we described at our recent Investor Day, WM is building distinctive platforms to drive competitive differentiation and fuel a powerful, long-term growth engine to create shareholder value. Our second quarter results are a strong demonstration of our progress on all fronts,&#8221; said Jim Fish, WM&#8217;s CEO. &#8220;Our Collection and Disposal business produced robust organic revenue growth and margin expansion, achieving the Company&#8217;s best-ever operating expense margin. We also grew operating EBITDA by double digits in both our Recycling Processing and Sales and WM Renewable Energy segments, as the earnings contributions from investments we have made in our sustainability businesses accelerate. Additionally, we continue to integrate our newest segment, WM Healthcare Solutions, and benefit from the impact of WM&#8217;s culture and operational excellence on customer relationships, cost efficiency, and financial results.&#8221;
Waste Management lowered its FY2025 sales guidance from $25.550 billion-$25.800 billion to $25.275 billion-$25.475 billion.
Waste Management shares fell 0.7% to trade at $233.95 on Wednesday.
These analysts made changes to their price targets on Waste Management following earnings announcement.
<ul class="wp-block-list">
<li>Oppenheimer analyst Noah Kaye maintained Waste Management with an Outperform rating and raised the price target from $260 to $265.</li>
<li>UBS analyst Jon Windham maintained the stock with a Neutral and raised the price target from $260 to $265.</li>
<li>BMO Capital analyst Devin Dodge maintained Waste Management with a Market Perform rating and raised the price target from $245 to $248.</li>
</ul>
Considering buying WM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/wm/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="573" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30151311/image-489-1024x573.png" alt="" class="wp-image-1007782" style="width:633px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30151311/image-489-1024x573.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30151311/image-489-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30151311/image-489-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30151311/image-489.png 1123w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46684052/jim-cramer-prefers-this-financial-stock-over-brighthouse-financial">Jim Cramer Prefers This Financial Stock Over Brighthouse Financial</a></li>
</ul>
Photo via Shutterstock

Waste Management Analysts Increase Their Forecasts After Strong Q2 Earnings

Pharmaceutical giants are navigating a complex landscape of fluctuating demand and regulatory hurdles, impacting their financial performance and strategic outlook. Merck &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) is the latest to face these challenges, as its recent earnings report reveals a mixed bag of <a href="https://www.benzinga.com/markets/earnings/25/07/46692220/merck-ceo-sees-minimal-eu-tariffs-impact-warns-of-gardasil-challenges">successes and setbacks.</a>
Merck reported a mixed second-quarter earnings picture on Tuesday. Adjusted earnings exceeded analyst consensus, but overall sales declined slightly year-over-year and fell short of revenue expectations.
<ul class="wp-block-list">
<li>MRK is consolidating close to its 52-week bottom. <a href="https://www.benzinga.com/quote/MRK" target="_blank" rel="noreferrer noopener">See real-time price here.</a></li>
</ul>
Investors were concerned about a significant drop in Gardasil vaccine sales, even as its blockbuster cancer drug Keytruda continued its strong growth trajectory.
Adjusted earnings per share of $2.13 surpassed <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimates</a> of $2.04, marking a decline from the $2.28 reported in the prior-year period.
Total sales of $15.81 billion, a 2% year-over-year decrease, narrowly missed analysts&#8217; projections of $15.94 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/m-a/25/07/46317822/merck-strikes-10-billion-deal-for-verona-secures-first-in-class-copd-drug" rel="noreferrer noopener">Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug</a>
Bank of America (BofA) Securities lowered the price forecast from <a href="https://www.benzinga.com/quote/MRK/analyst-ratings">$99 to $98, with a Buy rating</a>.
BofA says its revenue estimates are about 1% to 2% lower, mainly due to weaker Gardasil sales, though this is partly balanced by stronger Keytruda performance. Merck has said it won&#8217;t be shipping Gardasil to China in 2025, and this delay may continue into 2026. BofA&#8217;s core earnings estimates remain mostly the same.
Analyst Tim Anderson noted during the investor call that the primary focus, surprisingly, wasn&#8217;t on Gardasil, even though its slightly weaker Q2 performance likely caused the stock to drop 8% at the open before recovering to close just 2% lower.
Instead, most of the discussion centered on the company&#8217;s cancer drugs, such as Keytruda, and its cardiovascular and kidney treatments, including Winrevair. Overall, the rest of the business appears to be performing well.
MRK Price Action: Merck &amp; Co shares were down 0.53% at $82.19 at the time of publication on Wednesday<a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">, according to Benzinga Pro data.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/entertainment/25/07/46729590/netflix-hits-records-with-happy-gilmore-2-despite-lower-ratings-than-original-1996-film" target="_blank" rel="noreferrer noopener">Netflix Hits Records With &#8216;Happy Gilmore 2&#8217; Despite Lower Ratings Than Original 1996 Film</a></li>
</ul>
Photo: Shutterstock

Large Cap

Guidance

Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns

On Wednesday, GE HealthCare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NYSE">GEHC</a>) reported second-quarter 2025 adjusted earnings of $1.06 per share, which beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of 92 cents</a>. It was up from $1.00 a year ago.
The company reported sales of $5.01 billion, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46716016/ge-healthcare-reports-second-quarter-2025-financial-results" rel="noreferrer noopener">consensus of $4.96 billion</a>.
Revenues increased 3% on reported and 2% on an organic basis year-over-year. Revenue growth was driven by strength in the U.S. and Europe, the Middle East, and Africa.
Total company book-to-bill was 1.07 times. Total company orders increased 3% organically year-over-year.
The net income margin was 9.7% versus 8.9% for the prior year, which was up 80 basis points (bps) with lower tax and interest expenses.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/25/05/45662285/nvidia-unveils-foundation-models-for-humanoids-eyes-era-of-robotics-as-ai-spend-accelerates" rel="noreferrer noopener">Nvidia Unveils Foundation Models For Humanoids, Eyes &#8216;Era of Robotics&#8217; As AI Spend Accelerates</a>
Adjusted EBIT margin was 14.6% versus 15.3%, down 80 bps, impacted by tariffs, partially offset by benefits from productivity and volume.
GE HealthCare President and CEO Peter Arduini said, &#8220;We were pleased with solid orders and revenue performance in the second quarter across all segments, reflecting healthy customer investment in capital equipment. We also reported strong earnings performance while leveraging our lean capabilities and demonstrating progress on tariff mitigation&#8230;&#8221;
<h2 class="wp-block-heading">Guidance</h2>
GE HealthCare raises its fiscal 2025 adjusted earnings from $3.90-$4.10 per share to $4.43-$4.63 per share compared to the consensus of $4.07.
The earnings outlook includes approximately 45 cents of tariff impact.
Increased 2025 full-year guidance, reflective of healthy capital investment trends, operational execution, and changes in tariff rates.
Adjusted EBIT margin of 15.2%-15.4%, reflecting a decline of 110 bps to 90 bps versus the 2024 Adjusted EBIT margin of 16.3%; this compares to the previous Adjusted EBIT <a target="_blank" href="https://www.benzinga.com/25/04/45105997/ge-healthcare-q1-earnings-beat-expectations-tariffs-to-impact-2025-profit-outlook" rel="noreferrer noopener">margin guidance of 14.2%-14.4%</a>.
The company forecasts Free cash flow of at least $1.4 billion; this compares to previous Free cash flow guidance of at least $1.2 billion.
Price Action: GEHC stock is down 7.53% at $71.87 at the last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46727882/novo-nordisk-stock-hits-new-52-week-low-amid-profit-warning-what-investors-need-to-know" target="_blank" rel="noreferrer noopener">Novo Nordisk Stock Hits New 52-Week Low Amid Profit Warning: What Investors Need To Know</a></li>
</ul>
Photo by PixelBiss via Shutterstock

GEHC

GE HealthCare Core Operating Margin Faces Tariffs Heat, Raises Annual Outlook

<a href="https://www.youtube.com/watch?v=u0V3gnOjOi0">https://www.youtube.com/watch?v=u0V3gnOjOi0</a>
&nbsp;

Federal Reserve

Fed Chair Powell Says Totality Of Labor Market Data Shows Solid Market But You Have Downside Risks; It's Worth Paying Close Attention To It And We Are; The Discussion Around Policy, The Majority View Was That Inflation Is Above Target, Employment At Target, Policy Should Be Somewhat Restrictive; Expects Dissents To Be Explained In Next Day Or So; It's Not Surprising That There Are Differences; I Would Call It One Of The Better Meetings

Boeing Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) second-quarter results on Tuesday revealed a wider-than-anticipated loss, despite strong revenue driven by a significant jump in commercial aircraft deliveries and an expanding order backlog.
This mixed financial performance underscores the aerospace giant&#8217;s ongoing efforts to stabilize operations amid persistent industry challenges.
Despite the quarterly earnings per share (EPS) miss, Wall Street analysts largely maintain a bullish outlook on Boeing. They cite solid delivery momentum, a strong backlog, and improving cash flow as key reasons for optimism.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/earnings/25/07/46712908/trump-trade-deals-to-aid-600-billion-boeing-backlog-as-q2-reveals-tariffs-becoming-less-of-a-hea" rel="noreferrer noopener">Trump Trade Deals To Aid $600 Billion Boeing Backlog As Q2 Reveals Tariffs Becoming Less Of A Headwind</a>
Goldman Sachs analyst Noah Poponak, for instance, reiterated a Buy rating and modestly raised his <a target="_blank" href="https://www.benzinga.com/quote/BA/analyst-ratings" rel="noreferrer noopener">price forecast</a> to $260 from $257, citing stronger-than-expected commercial deliveries and cash flow.
Similarly, Bank of America Securities (BofA) analyst Ronald J. Epstein maintained a Buy rating with a reaffirmed price forecast of $260, buoyed by robust jet demand and improving execution.
Boeing reported <a target="_blank" href="https://www.benzinga.com/markets/earnings/25/07/46689269/boeing-commercial-airplane-revenue-recovers-backlog-grows-to-619-billion" rel="noreferrer noopener">second-quarter</a> revenue of $22.75 billion, topping analyst expectations thanks to a 63% jump in commercial aircraft deliveries. However, the company posted an adjusted loss of $1.24 per share, wider than the $0.94 loss forecast, partly due to a $445 million charge tied to a Department of Justice settlement. Free cash outflow came in at $200 million, beating consensus estimates by over $1 billion.
Commercial airplane revenue surged 81% year-over-year to $10.87 billion. Boeing delivered 150 commercial jets during the quarter, helping backlog swell to $619 billion, including more than 5,900 aircraft orders worth $522 billion. The 737 program remained steady at 38 units per month, while the 787 ramped up to 7 per month.
<h2 class="wp-block-heading">Analyst Take: Cautious Optimism With Focus On Execution</h2>
Goldman&#8217;s Poponak views Boeing&#8217;s second-quarter results as a broad beat, driven by stronger Commercial Aircraft deliveries, stabilized Defense margins, and solid Services performance. Free cash flow exceeded consensus by over $1 billion, prompting an upward revision to full-year guidance. While 737 and 787 production rates remain at 38 and 7 per month, respectively, demand supports further increases.
Poponak believes Boeing must still improve operational execution to restore normalized margins and regain investor confidence. If achieved, the stock offers substantial upside. He maintains a Buy rating with a revised $260 price target, based on a 3.0% FCF yield on 2026E. Key risks include supply chain constraints, air traffic growth uncertainty, and defense contract execution.
BofA&#8217;s Epstein maintains a Buy rating on Boeing after the second-quarter results, noting a strong free cash flow beat despite an EPS miss caused by a $445 million non-operating charge. He points to the ($200 million) FCF, well ahead of the ($1.8 billion) estimate, as a sign of improving execution through inventory drawdown and working capital gains.
Boeing beat free cash flow expectations, gaining altitude with strong operational performance, and plans to request a production rate increase for its 737 aircraft. This reflects confidence in the rising demand for commercial jets.
While Commercial and Defense margins came in below expectations, Epstein sees encouraging signals in Boeing&#8217;s plan to raise 737 MAX production to 42/month and a robust $522 billion backlog.
The price forecast of $260 is based on $9/share normalized FCF and a 1.2x S&amp;P 500 multiple. He cites strong jet demand and the F-47 ramp. Risks include the execution of new programs, labor constraints, and macro shocks to aviation demand.
Boeing said it remains focused on restoring trust, stabilizing operations, and executing on production targets amid a dynamic global backdrop. The company reaffirmed plans to increase 737 output later this year and emphasized continued progress on safety, quality, and long-term recovery.
Other analysts have also provided updates on the stock. RBC Capital&#8217;s Ken Herbert reiterated an Outperform rating, maintaining his price forecast at $250. UBS analyst Gavin Parsons maintained a Buy rating and increased the price forecast from $255 to $280.
JP Morgan&#8217;s Seth Seifman reaffirmed an Overweight rating, lifting the forecast from $230 to $251. Susquehanna&#8217;s Charles Minervino held a Positive rating while increasing the forecast from $265 to $270. Lastly, Barclays analyst David Strauss also maintained an Overweight stance and raised the price forecast from $210 to $255.
Price Action: BA shares are trading higher by 0.81% at $227.92 on Wednesday&#8217;s last check.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46727223/old-dominion-freight-line-ceo-remains-confident-in-long-term-growth-despite-downturn" target="_blank" rel="noreferrer noopener">Old Dominion Freight Line CEO Remains Confident In Long-Term Growth Despite Downturn</a></li>
</ul>
Photo by Michael Vi via Shutterstock

Reiteration

Analysts Confident Boeing Is 'Gaining Altitude' Despite Q2 Loss

Politics

Reuters Cites Brazil's Ceron Saying The Exclusion Of Some Products From Higher Taxation By The U.S. Covers Relevant Items, It Is Relevant News; We Work On The Contingency Plan To Calibrate Measures For The Most Affected Sectors; I Do Not Believe That The Exclusion Of Some Products Will Require Major Adjustments To Our Contingency Plan; We Are Not In The Worst Case Scenario With Exceptions For Higher U.S. Tariffs, It Is A More Benign Scenario Than It Could Be

Fed Chair Powell Says Consumer Spending Had Been Very Very Strong For Last Few Years And Now Maybe It Has Finally Slowed Down; It Is At A Healthy Level And Performance Of Credit Has Been Good; GDP Was Right In Line With What We Expected, But Still Difficult To Interpret Because Of Net Exports Swings; Private Sector Job Creation In Last Report Had Come Down A Bit; The Flow Into Labor Force Is A Great Deal Slower, Largely From Immigration Policy

Brown &amp; Brown Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) reported upbeat earnings for the second quarter after the <a href="https://www.benzinga.com/quote/BRO/earnings">closing bell on Monday</a>.
The company posted quarterly earnings of $1.03 per share which beat the analyst consensus estimate of 99 cents per share. The company reported quarterly sales of $1.285 billion which beat the analyst consensus estimate of $1.277 billion.
Brown &amp; Brown shares rose 1% to trade at $92.85 on Wednesday.
These analysts made changes to their price targets on Brown &amp; Brown following earnings announcement.
<ul class="wp-block-list">
<li>B of A Securities analyst Joshua Shanker upgraded Brown &amp; Brown from Neutral to Buy and raised the price target from $126 to $130.</li>
<li>Wells Fargo analyst Elyse Greenspan maintained the stock with an Overweight rating and cut the price target from $127 to $104.</li>
<li>BMO Capital analyst Michael Zaremski maintained the stock with an Outperform rating and lowered the price target from $122 to $106</li>
</ul>
Considering buying BRO stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="572" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30150626/image-488-1024x572.png" alt="" class="wp-image-1007768" style="width:603px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30150626/image-488-1024x572.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30150626/image-488-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30150626/image-488-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30150626/image-488.png 1113w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46684052/jim-cramer-prefers-this-financial-stock-over-brighthouse-financial"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46684052/jim-cramer-prefers-this-financial-stock-over-brighthouse-financial">Jim Cramer Prefers This Financial Stock Over Brighthouse Financial</a></li>
</ul>
Photo via Shutterstock

These Analysts Revise Their Forecasts On Brown & Brown Following Q2 Results

With Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) preparing to <a href="https://www.benzinga.com/trading-ideas/previews/25/07/46698434/microsoft-q4-preview-can-the-tech-giant-beat-forecasts-for-10th-straight-quarter">report fourth-quarter results after markets close today</a>, expectations are high, both for the tech giant and the <a href="https://www.benzinga.com/etfs">ETFs riding its AI wave</a>. Wall Street analysts are estimating revenue of $73.8 billion and earnings per share of close to $3.37. 
Azure&#8217;s cloud growth is expected to be 34–35%, with much of it attributed to the company&#8217;s aggressive expansion in generative AI, according to Investors Business Daily.
While, however, investors scrutinize Microsoft&#8217;s figures, AI-themed ETFs are already getting a tailwind.
<h2 class="wp-block-heading">AI ETFs In Focus</h2>
Thematic ETFs such as the Global X Artificial Intelligence &amp; Technology ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIQ#NASDAQ">AIQ</a>) and ROBO Global Artificial Intelligence ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THNQ#NYSE">THNQ</a>) have recently gained popularity, with Microsoft frequently being among their top holdings. AIQ, for example, has Microsoft in its highest 10 and has risen 3% in the last month and 17% year-to-date, mirroring the wider turnaround in AI sentiment. THNQ is up more than 3% in the last month and 16% YTD, although the fund is diversified with mostly equal weightages given to each holding.
The other significant ETF, Dan Ives&#8217; Wedbush AI Revolution ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVES#NYSE">IVES</a>), which launched in June, also has Microsoft as one of its main exposure points. Although still in its infancy, IVES has already collected almost $400 million in AUM, capitalizing on the AI boom story.
Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/06/45982240/beyond-magnificent-7-can-thematic-etfs-like-ives-lead-the-next-wave-of-ai-investing-cio-cullen-rogers-explains">Beyond Magnificent 7: Can Thematic ETFs Like IVES Lead The Next Wave Of AI Investing? CIO Cullen Rogers Explains</a>
<h2 class="wp-block-heading">Why Azure Matters To ETFs</h2>
Azure&#8217;s performance has become a proxy for Microsoft&#8217;s execution on enterprise AI demand. With offerings such as Copilot for Office 365 and collaborations with OpenAI, Azure is rapidly emerging as the heartbeat of Microsoft&#8217;s AI monetization plan. Any upside surprise in the growth of Azure might trigger a ripple effect in AI ETFs with heavy Microsoft allocations or those concentrated in enterprise AI plays.
On the other hand, any indication of slowdown, particularly with continued cost pressures, would put ETFs with significant exposure to the stock under heavy pressure.
In brief, Microsoft&#8217;s earnings are a read on the overall AI investing universe. And ETFs, especially thematic AI indexes, are right in the middle.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/07/46731965/metas-ai-firepower-could-ignite-magnificent-seven-etfs">Meta&#8217;s AI Firepower Could Ignite Magnificent Seven ETFs</a></li>
</ul>
Image: Shutterstock

Sector ETFs

ETFs

IVES

MSFT

THNQ

Microsoft's $74 Billion AI Surprise? ETFs Bet Big On Azure's Secret Weapon

SCCO

Reuters Cites White House Proclamation Saying U.S. Commerce Secretary By June 30 2026 Will Provide Update On Domestic Copper Markets; Trump Will Evaluate Whether To Impose Phased Universal Import Duty On Refined Copper Of 15% Starting Jan. 1 2027

Refinancing arranged for Kushner Real Estate Group &amp; National Real Estate Advisors' Journal Squared III in Hudson County
MORRISTOWN, N.J., July 30, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4478635-1&amp;h=2327021164&amp;u=http%3A%2F%2Fwww.jll.com%2F&amp;a=JLL">JLL</a>'s Capital Markets group announced today that it has secured a $255 million refinancing for Journal Squared III, a newly constructed, 58-story luxury multifamily high-rise in the Journal Square neighborhood of Jersey City, New Jersey.
JLL worked on behalf of the borrower, a joint-venture between Kushner Real Estate Group ("KRE") and National Real Estate Advisors, LLC ("NATIONAL"), in arranging the 12-year fixed-rate loan through Pacific Life.

JLL's Capital Markets Group Secures $255M Refinancing For Journal Squared III In Jersey City

<a href="https://www.youtube.com/watch?v=u0V3gnOjOi0" title="https://www.youtube.com/watch?v=u0V3gnOjOi0">https://www.youtube.com/watch?v=u0V3gnOjOi0</a>

Fed Chair Powell Says Consumers Will Pay Some Of The Cost Of Tariffs, Retailers Will Pay Some Of It; Goods Inflation Moving Us Away A Bit But Not Very Far Away From Target; We Have Risks To Both Of Our Goals; A Pretty Reasonable Base Case Is That This Will Be A One-time Price Increase; We're Trying To Get The Timing Right; Government Data Is The Gold Standard And We Need It To Be Good And To Rely On It; Certainly Hope We Get What We Need; Having An Independent Central Bank Has Served The Public Well

Standex International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXI#NYSE">SXI</a>) is set to give its latest quarterly earnings report on Thursday, 2025-07-31. Here's what investors need to know before the announcement.
Analysts estimate that Standex International will report an earnings per share (EPS) of $2.10. 
The market awaits Standex International's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
The company's EPS beat by $0.03 in the last quarter, leading to a 9.8% increase in the share price on the following day.
Here's a look at Standex International's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.92</td>
<td>1.67</td>
<td>1.70</td>
<td>1.72</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.95</td>
<td>1.91</td>
<td>1.71</td>
<td>1.76</td>
</tr>
<tr>
<td>Price Change %</td>
<td>10.0%</td>
<td>-2.0%</td>
<td>4.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753902206_0.png" alt="eps graph" />
<h3>Market Performance of Standex International's Stock</h3>
Shares of Standex International were trading at $165.29 as of July 29. Over the last 52-week period, shares are down 7.82%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Analysts' Perspectives on Standex International</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Standex International.
Analysts have given Standex International a total of 3 ratings, with the consensus rating being Outperform. The average one-year price target is $213.33, indicating a potential 29.06% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Kennametal, Albany International and Hillman Solns, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Kennametal, with an average 1-year price target of $23.0, suggesting a potential 86.09% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Albany International, with an average 1-year price target of $71.0, suggesting a potential 57.05% downside.</li>
<li>Analysts currently favor an Buy trajectory for Hillman Solns, with an average 1-year price target of $9.5, suggesting a potential 94.25% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
In the peer analysis summary, key metrics for Kennametal, Albany International and Hillman Solns are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standex International</td>
<td>Outperform</td>
<td>17.21%</td>
<td>$82.43M</td>
<td>3.26%</td>
</tr>
<tr>
<td>Kennametal</td>
<td>Neutral</td>
<td>-5.70%</td>
<td>$156.37M</td>
<td>2.56%</td>
</tr>
<tr>
<td>Albany International</td>
<td>Neutral</td>
<td>-7.84%</td>
<td>$96.49M</td>
<td>1.88%</td>
</tr>
<tr>
<td>Hillman Solns</td>
<td>Buy</td>
<td>2.58%</td>
<td>$168.60M</td>
<td>-0.03%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Standex International ranks highest in Revenue Growth among its peers. It also leads in Gross Profit. However, it ranks lowest in Return on Equity.
<h3>Delving into Standex International's Background</h3>
Standex International Corp is an industrial manufacturer of different products and services used in commercial and industrial markets. It has five reportable segments; Electronics; Engraving; Scientific; Engineering Technologies and Specialty Solutions. The maximum revenue is generated from its Electronics segment which is a component and value-added services provider of both sensing and switching technologies as well as magnetic power conversion components and assemblies, like custom wound transformers and inductors, current sense technology, value-added assemblies, and mechanical packaging among others. Geographically, it derives key revenue from the United States and the rest from Asia Pacific, Europe, Middle East and South Africa (EMEA), and other regions.
<h3>Financial Insights: Standex International</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Standex International displayed positive results in 3 months. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 17.21%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 10.53%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Standex International's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.26% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Standex International's ROA excels beyond industry benchmarks, reaching 1.44%. This signifies efficient management of assets and strong financial health.
Debt Management: Standex International's debt-to-equity ratio surpasses industry norms, standing at 0.91. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<a href="https://www.benzinga.com/quote/SXI/earnings">To track all earnings releases for Standex International visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Peek at Standex International's Future Earnings

Press Releases

Coincheck Group N.V. to Announce Third Quarter 2025 Results on February 12, 2025

Coincheck Reports Fiscal 2025 Third Quarter Financial Results

Japan Go IPO Summit Announces Roster of Expert Speakers for Event June 5th in Tokyo

/C O R R E C T I O N -- Marcum Asia CPAs LLP/

Coincheck Group N.V. to Announce Fourth Quarter 2025 Results on May 13, 2025

Coincheck Reports Financial Results for Fourth Quarter and Year Ended March 31, 2025

Coincheck Group N.V. to Announce Financial Results for First Quarter of Year Ending March 31, 2026 on August 7, 2025

Comments

Coincheck Group

Intérêt court

Coincheck Group (NASDAQ:CNCK) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL